We’re currently experiencing extremely high call volumes. We’re very sorry for any inconvenience this might cause.

If you need help with your account, please visit our Help Centre, or email us and we’ll get back to you as soon as we can. For more information and tips on managing your account online please visit www.hl.co.uk/coronavirus

We’re experiencing high call volumes, please check FAQs before calling.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Biohaven Pharmaceutical Holding Company Ltd (BHVN) NPV

Sell:$35.26 Buy:$35.27 Change: $0.53 (1.48%)
Market closed |  Prices as at close on 27 March 2020 | Switch to live prices |
Sell:$35.26
Buy:$35.27
Change: $0.53 (1.48%)
Market closed |  Prices as at close on 27 March 2020 | Switch to live prices |
Sell:$35.26
Buy:$35.27
Change: $0.53 (1.48%)
Market closed |  Prices as at close on 27 March 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. The Company's glutamate platform includes three clinical-stage product candidates being developed for the treatment of various neurological indications: trigriluzole for the treatment of obsessive-compulsive disorder (OCD), spinocerebellar ataxia (SCA) and Alzheimer's disease; BHV-0223 for the treatment of amyotrophic lateral sclerosis (ALS), and BHV-5000 for the treatment of neurological and psychiatric illnesses such as Rett syndrome, neuropathic pain and treatment-resistant depression. BHV-0223 is developing for the treatment of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord.

Contact details

Address:
215 Church St
NEW HAVEN
06510-1803
United States
Telephone:
+1 (203) 4040410
Website:
biohavenpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BHVN
ISIN:
VGG111961055
Market cap:
$2.09 billion
Shares in issue:
58.29 million
Sector:
Biotechnology
Exchange:
New York Stock Exchange
Country:
Virgin Islands
Currency:
US dollar
Indices:
n/a

Key personnel

  • Thomas Lynch
    Chairman of the Board
  • Vlad Coric
    Chief Executive Officer, Director
  • James Engelhart
    Chief Financial Officer, Treasurer
  • Kimberly Gentile
    Senior Vice President - Clinical Operations
  • Charles Conway
    Chief Scientific Officer
  • Robert Berman
    Chief Medical Officer
  • John Tilton
    Chief Commercial Officer, Rare and Orphan Diseases

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.